Bristol-Myers Squibb Company Retained Earnings Growth: 3.39%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMY Retained Earnings Growth Rankings
| Overall | 24th percentile | 1865 of 2482 |
| Sector | 14th percentile | 152 of 177 in Healthcare |
| Industry | 16th percentile | 10 of 12 in Drug Manufacturers - Major |
BMY Retained Earnings Growth Range, Past 5 Years
| Minimum | -7.96% | Mar 2003 |
| Maximum | 51.12% | Sep 1990 |
| Average |
About Retained Earnings Growth
Retained Earnings Growth is the percent increase/decrease of a company's retained net income over time. A company can use retained earnings to maintain current operations, or to invest in new ventures. Generally speaking, retained earnings growth is accompanied by subsequent increases in sales and profitability.
If a company's retained earnings at the end of 2008 were $12 million, and by the end of 2009 the company's retained earnings increased to $15 million, the company experienced a retained earnings growth of 25%.
Learn More
You may also be interested in these BMY related companies
BMY News
$BMY http://stks.co/2MSX Continues towards the Median Line of Red pitchfork, down!
about a day ago by harmongreg
about a day ago by harmongreg
Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference
Feb 08, 3:19PM Business Wire
Feb 08, 3:19PM Business Wire
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Feb 08, 6:52AM Street Insider
Feb 08, 6:52AM Street Insider
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Feb 08, 1:30AM Business Wire
Feb 08, 1:30AM Business Wire
$AEP bullish channel long setup #trading $SPY $SPX $BMY http://chart.ly/wnu25wq
about 6 days ago by dariabarbu75
about 6 days ago by dariabarbu75
YCHARTS DIVIDEND DAILY: Dividends Are Hot – Help For Finding Some Below – But Know the Risks, Too http://stks.co/2Geb $BMY $EXC $CEG $PEP
about 6 days ago by ycharts
about 6 days ago by ycharts
$BMY http://stks.co/2Fgm Through Hagopian Trigger, next target ML of red pitchfork near 31.40
about 7 days ago by harmongreg
about 7 days ago by harmongreg
$BMY looking like forming support at 32 level on sustained volume. http://chart.ly/2psfb3p
about 11 days ago by Sirtuan
about 11 days ago by Sirtuan
$BMY setting up a perfect entry point here with tight stop. Fingers crossed
about 11 days ago by aceTR8DER
about 11 days ago by aceTR8DER
intraday $BMY pierced above & closed right @ 10DMA support trend line. possible entry in formation. http://stks.co/2CMl #dividends
about 11 days ago by stubbybrown
about 11 days ago by stubbybrown
Listen to $BMY Q4 2011 earnings call (EPS 0.63 vs est 0.55) - live at 10:30 AM, ondemand after - http://stks.co/26el
about 18 days ago by earningscast
about 18 days ago by earningscast
$BMY $CTXS have already gone red/green premkt after earnings...$POT may be next.
about 18 days ago by TER_Intraday
about 18 days ago by TER_Intraday
EBR: Watchlist/worksheet/3 Trading Ideas: $BMY $NKA $PLCE $SVM http://stks.co/26Vj
about 18 days ago by TER_Intraday
about 18 days ago by TER_Intraday
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMY | 31.90 | -0.09 | -0.28% | 54.06B |
| JPM | 37.61 | -0.25 | -0.66% | 142.91B |
| XOM | 83.80 | -1.08 | -1.27% | 401.67B |
| BAC | 8.07 | -0.11 | -1.34% | 81.78B |
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
| NRG | 17.32 | 0.24 | 1.41% | 4.18B |
| AIG | 26.66 | -0.69 | -2.52% | 50.60B |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
| CVS | 43.18 | 0.18 | 0.42% | 56.20B |
